Information Provided By: 
Fly News Breaks for October 29, 2018
RIGL
Oct 29, 2018 | 10:28 EDT
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Rigel Pharmaceuticals with an $8 price target following this morning's announcement that an agreement has been reached with Kissei Pharmaceutical to bring Tavalisse to market in Asia. The analyst expected a deal like this, but not until the first half of 2019. He's "encouraged "by Tavalisse's continued progress and remains a buyer of Rigel Pharmaceuticals shares.
News For RIGL From the Last 2 Days
There are no results for your query RIGL
